---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-018231"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:40:04.133791+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics President, COO and Director Amy Broidrick to resign effective June 16, 2023

## Summary
- Amy Broidrick, President, Chief Strategy and Operating Officer, and director, submitted resignation effective June 16, 2023.
- Her departure is not related to any disagreement with the company on operations, policies, or practices.
- She will resign from all officer and director positions with the company and its subsidiaries.
- Company intends to enter into a separation agreement and general release with Ms. Broidrick.

## SEC filing metadata
- accession: 0001493152-23-018231
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/0001493152-23-018231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-018231
- JSON: https://secwatch.observer/filing/0001493152-23-018231.json
- Plain text: https://secwatch.observer/filing/0001493152-23-018231.txt

## Key facts
- Executive change
  Amy Broidrick resigned as President, Chief Strategy and Operating Officer and Director at AIxCrypto Holdings, Inc..
  - Action: resigned
  - Role: President, Chief Strategy and Operating Officer and Director
  source text: On May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which will become effective June 16, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315223018231/0001493152-23-018231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.